Checkpoint inhibitor
-
As the 10th anniversary of approval approaches，Keytruda adds ‘potential’ performance to Merck
DrugTimes will follow up on this subject. Please stay tuned
-
A PD-L1 siRNA that Can Boost Immune Response for CHB Functional Cure 【Product for Licensing】
If you are interested in this product, please contact us at BD@drugtimes.cn. Many thanks!
